Study group background characteristics. by Zicheng Hu (3825313)

“…This ratio was disrupted when blood CD4+ T-cells fell to <50 cells/μL and the CSF WBC count decreased to negligible levels; in this group the CSF:blood HIV-1 RNA ratio decreased nearly 10-fold to an overall ratio of <1:100. …”

Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Supplementary Material for: Efficacy of penetrating canaloplasty versus trabeculectomy in patients with bilateral primary glaucoma: a self-control study by figshare admin karger (2628495)

“…Complete (without medication) and qualified success (with/without medication) were defined as IOP ≤21 mmHg and ≥20% IOP reduction. Results: Mean IOP decreased from 32.5±8.87mmHg on 2.3±1.43 medications at baseline to 14.6±4.41mmHg on 0.20±0.58 medications at 12 months in TRAB group (both p<0.0001) and from 30.0±9.61mmHg on 2.7±1.10 medications to 14.8±4.63mmHg on 0.12±0.44 medications in PCP group (both p<0.0001). …”

Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Supporting data for "The Mediating and Moderating Factors in the Association between Tooth Loss and Cognitive Decline" by Huimin Chen (12992361)

“…<p dir="ltr">Dementia has emerged as significant public health concerns, with Alzheimer's disease (AD) constituting the predominant subtype. …”

<i>Tg</i>ATM1-depleted <i>Toxoplasma</i> are functionally complemented through expression of the <i>Plasmodium</i> or yeast homolog. by Deepti Shrivastava (17715780)

“…The number of significantly increased and decreased proteins is given and the NEET proteins CDGSH1 and CDGSH2 as well as <i>Tg</i>ATM1 are indicated.…”

Flow Chart of the Study Steps. by Azam Hosseinpour (13434515)

“…</p><p>Conclusion</p><p>The IP-GBL enhanced germane cognitive load and decreased the intrinsic and extrinsic cognitive load, which facilitated students’ learning. …”

Data Sheet 1_Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study.pdf by Sam Salek (5800727)

“…Background<p>Disease-specific factors associated with decreased quality of life (QoL) in patients with leukemia have not been studied in a large-scale, global, observational study.…”

Data Sheet 2_Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study.docx by Sam Salek (5800727)

“…Background<p>Disease-specific factors associated with decreased quality of life (QoL) in patients with leukemia have not been studied in a large-scale, global, observational study.…”

Included studies basic characteristics. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

DataSheet1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

DataSheet2_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

All data extracted. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”